SCHEMBL29454136

SCHEMBL29454136

Cc1c(N)cc(Cl)cc1N(C)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHKA P35790 8/20 0.42
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
CHKB Q9Y259 2/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
CSF1R P07333 1/20 0.36
CYP3A4 P08684 2/20 0.36
EGFR P00533 1/20 0.33
GSK3B P49841 1/20 0.33
DHFR P00374 1/20 0.33
CRHR1 P34998 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31723209 0.87 EGFR (0.44) CHKAGAAKMT2AMAPTHPGD
SCHEMBL29454084 0.87 EGFR (0.44) CHKAGAAKMT2AMAPTHPGD
SCHEMBL22232059 0.87 EGFR (0.44) CHKAGAAKMT2AMAPTHPGD
SCHEMBL29454103 0.86 L3MBTL1 (0.39) GAAKMT2ALMNATSHRMAPK13
SCHEMBL31723252 0.86 L3MBTL1 (0.39) GAAKMT2ALMNATSHRMAPK13
SCHEMBL31723238 0.83 ABCG2 (0.36) GAAKMT2AMAPK13MAPK12MAPK11
SCHEMBL22231907 0.83 ABCG2 (0.36) GAAKMT2AMAPK13MAPK12MAPK11
SCHEMBL29454192 0.83 ABCG2 (0.36) GAAKMT2AMAPK13MAPK12MAPK11
SCHEMBL29454184 0.82 CYP3A4 (0.39) GAAKMT2AHPGDALOX15TSHR
SCHEMBL22232413 0.81 TUBB3 (0.38) GAAKMT2AMAPTEGFRDHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US claimed
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP claimed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US claimed
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof PI INDUSTRIES LTD. (IN) 2026-02-10 US disclosed
EP-4647426-A2 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI Industries Ltd. (IN) 2025-11-12 EP disclosed
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF PI INDUSTRIES LTD. (IN) 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089523-A1 3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF H1-3, PRMT7, PFAS CHKA 3757/4885GAA 1080/4885KMT2A 438/4885
US-12545639-B2 3-substituted phenylamidine compounds, preparation and use thereof CBR1, CBR3, HCCS CHKA 617/4885GAA 2001/4885KMT2A 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.